ABL Bio Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Sang Hoon Lee
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.1yrs |
| CEO ownership | 27.4% |
| Management average tenure | 3.1yrs |
| Board average tenure | no data |
Recent management updates
No updates
Recent updates
Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%
Nov 20
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Mar 31Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?
Jan 20
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Dec 16CEO
Sang Hoon Lee
9.1yrs
Tenure
Dr. Sang Hoon Lee, PH D co-founded PharmAbcine, Inc. in 2008 and serves as its Executive Vice President. Dr. Lee founded ABL Bio Inc. in February 2016 and serves as its President and Chief Executive Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.1yrs | no data | 27.41% ₩ 481.0b | |
| Executive VP | no data | no data | 1.55% ₩ 27.1b | |
| Executive VP & COO | no data | no data | no data | |
| Executive VP | 3.1yrs | no data | 1.42% ₩ 25.0b | |
| Executive VP & Chief of Discovery | no data | no data | no data | |
| Executive VP | no data | no data | no data | |
| Head of Medical & Clinical Development | 3.1yrs | no data | no data |
3.1yrs
Average Tenure
Experienced Management: A298380's management team is considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 00:42 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ABL Bio Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| Haesoon Kwon | Eugene Investment & Securities Co Ltd. |
| Jihoon Shin | LS Securities Co., Ltd. |